WO2011151619A1 - Composés destinés au traitement d'une maladie associée à clostridium difficile - Google Patents

Composés destinés au traitement d'une maladie associée à clostridium difficile Download PDF

Info

Publication number
WO2011151619A1
WO2011151619A1 PCT/GB2011/000829 GB2011000829W WO2011151619A1 WO 2011151619 A1 WO2011151619 A1 WO 2011151619A1 GB 2011000829 W GB2011000829 W GB 2011000829W WO 2011151619 A1 WO2011151619 A1 WO 2011151619A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compounds
agents
pyridin
halo
Prior art date
Application number
PCT/GB2011/000829
Other languages
English (en)
Inventor
Peter David Johnson
Richard Vickers
Francis Xavier Wilson
Colin Richard Dorgan
Original Assignee
Summit Corporation Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1009104.9A external-priority patent/GB201009104D0/en
Priority claimed from GBGB1106985.3A external-priority patent/GB201106985D0/en
Application filed by Summit Corporation Plc filed Critical Summit Corporation Plc
Publication of WO2011151619A1 publication Critical patent/WO2011151619A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the spores can be readily prepared as a dry powder that can be disseminated by numerous methods and used as a bioterrorist agent.
  • Anthrax is considered the single most worrying bioterrorism agent ⁇ CDC Emerg. Infect. Dis., 2004, 5 (4), 552-555). This can be highlighted by the postal anthrax attacks in the United States in 2001. There were 22 confirmed infections resulting in 5 deaths with the cost of cleanup and decontamination following the attacks estimated at $1 billion.
  • CDAD therapies include provision of Saccharomyces boulardii or Lactobacillus acidophilus in conjunction with antibiotics, faecal transplantation and in severe cases where all other therapy options have failed, surgery. Although rates of colectomy are low (up to 3% of cases) it is associated with high mortality rates (up to 60%).
  • the term “consisting” is used to indicate the presence of the recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) alone.
  • the term “disease” is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms. The term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition or syndrome in which physiological function is impaired irrespective of the nature of the aetiology (or indeed whether the aetiological basis for the disease is established). It therefore encompasses conditions arising from trauma, injury, surgery, radiological ablation, poisoning or nutritional deficiencies.
  • a prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • C 2 -C 6 alkenyl refers to a straight or branched hydrocarbon chain having from two to six carbon atoms and containing at least one carbon-carbon double bond. Examples include ethen l, 2-propenyl, and 3-hexenyl.
  • heteroaryl * are aryl moieties as defined above which contain heteroatoms (e.g. nitrogen, sulphur and/or oxygen).
  • the term also includes systems in which a ring having aromatic character is fused to a saturated or partially saturated ring. Examples include pyridine, pyrimidine, furan, thiophene, indole, isoindole, indoline, benzofuran, benzimidazole, benzimidazoline quinoline, isoquinoline,
  • the invention also contemplates the use of one or more of the following adjunctive agents as further components of the invention.
  • the invention provides compositions comprising the compound of the invention in combination with one or more adjunctive agents selected from those described below.
  • compositions can include stabilizers, antioxidants, colorants and diluents.
  • Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not compromised to such an extent that treatment is ineffective.
  • Sweetening agents such as those set forth above, and flavouring agents can be added to provide a palatable oral preparation. These compositions can be preserved by addition of an antioxidant such as ascorbic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des composés de formule (I) ou sur un N-oxyde, un sel, un hydrate, un produit de solvatation, un complexe, un bioisostère, un métabolite ou un promédicament de ces composés, qui peuvent être utilisés pour le traitement d'une infection à Clostridium difficile et de maladies provoquées par Clostridium difficile.
PCT/GB2011/000829 2010-06-01 2011-06-01 Composés destinés au traitement d'une maladie associée à clostridium difficile WO2011151619A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1009104.9 2010-06-01
GBGB1009104.9A GB201009104D0 (en) 2010-06-01 2010-06-01 Compounds for the treatment of clostridium difficile associated disease
GB1106985.3 2011-04-27
GBGB1106985.3A GB201106985D0 (en) 2011-04-27 2011-04-27 Compounds for the treatment of clostridium difficile associated disease

Publications (1)

Publication Number Publication Date
WO2011151619A1 true WO2011151619A1 (fr) 2011-12-08

Family

ID=45066235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/000829 WO2011151619A1 (fr) 2010-06-01 2011-06-01 Composés destinés au traitement d'une maladie associée à clostridium difficile

Country Status (1)

Country Link
WO (1) WO2011151619A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019371A1 (fr) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Composés organiques volatils (cov) utilisables en vue du diagnostic de la diarrhée associée à clostridium difficile (dacd)
EP3628669A1 (fr) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Nouveaux composés en tant qu'inhibiteurs de la nadph oxydase
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824698A (en) 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
WO2000063180A1 (fr) * 1999-04-16 2000-10-26 The University Of Reading Bis-benzazoles et utilisation de ces derniers en tant qu'agents antineoplasiques
WO2002060879A2 (fr) 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Inhibiteurs de la gyrase et utilisations associees
WO2003105846A1 (fr) 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated Derives d'acide 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylique et composes associes utilises comme inhibiteurs de la gyrase et/ou de la topoisomerase iv aux fins de traitement d'infections bacteriennes
WO2004001058A2 (fr) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Composes modulateurs de facteurs de transcription et procedes d'utilisation
WO2004041209A2 (fr) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Composés modulant le facteur de transcription et méthodes d'utilisation de ces derniers
US20060036061A1 (en) * 2004-08-11 2006-02-16 Chong-Kyu Shin Novel benzimidazole compound
WO2006076009A2 (fr) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Composes de modulation de facteur de transcription et leurs procedes d'utilisation
US20070112048A1 (en) 2005-08-12 2007-05-17 Sina Bavari Broad Spectrum Antibacterial Compounds
WO2007056330A1 (fr) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Derives de benzimidazole utilises en tant qu'inhibiteurs de la gyrase
WO2007148093A1 (fr) 2006-06-22 2007-12-27 Prolysis Ltd. Compositions antibactériennes
US20100033088A1 (en) * 2008-08-07 2010-02-11 Samsung Mobile Display Co., Ltd. Heterocyclic compound and organic electroluminescent device comprising the same
WO2010063996A2 (fr) * 2008-12-02 2010-06-10 Summit Corporation Plc Composés antibactériens

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824698A (en) 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
WO2000063180A1 (fr) * 1999-04-16 2000-10-26 The University Of Reading Bis-benzazoles et utilisation de ces derniers en tant qu'agents antineoplasiques
WO2002060879A2 (fr) 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Inhibiteurs de la gyrase et utilisations associees
WO2004001058A2 (fr) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Composes modulateurs de facteurs de transcription et procedes d'utilisation
WO2003105846A1 (fr) 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated Derives d'acide 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylique et composes associes utilises comme inhibiteurs de la gyrase et/ou de la topoisomerase iv aux fins de traitement d'infections bacteriennes
WO2004041209A2 (fr) 2002-11-01 2004-05-21 Paratek Pharmaceuticals, Inc. Composés modulant le facteur de transcription et méthodes d'utilisation de ces derniers
WO2006076009A2 (fr) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Composes de modulation de facteur de transcription et leurs procedes d'utilisation
US20060036061A1 (en) * 2004-08-11 2006-02-16 Chong-Kyu Shin Novel benzimidazole compound
US20070112048A1 (en) 2005-08-12 2007-05-17 Sina Bavari Broad Spectrum Antibacterial Compounds
WO2007056330A1 (fr) 2005-11-07 2007-05-18 Vertex Pharmaceuticals Incorporated Derives de benzimidazole utilises en tant qu'inhibiteurs de la gyrase
WO2007148093A1 (fr) 2006-06-22 2007-12-27 Prolysis Ltd. Compositions antibactériennes
US20100033088A1 (en) * 2008-08-07 2010-02-11 Samsung Mobile Display Co., Ltd. Heterocyclic compound and organic electroluminescent device comprising the same
WO2010063996A2 (fr) * 2008-12-02 2010-06-10 Summit Corporation Plc Composés antibactériens

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"Antibiotic Treatment for Clostridium difficile-Associated Diarrhea in Adults", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 3, 2007
"Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
ALIMENT. PHARM. THER., vol. 15, no. 9, 2001, pages 1445 - 1452
ALIMENT. PHARMACOL. THER., vol. 15, no. 5, 2001, pages 613 - 624
AM. J. GASTROENTEROL., vol. 93, no. 7, 1998, pages 1175 - 1176
ANTIMICROB. AGENTS CHEMOTHER., vol. 28, no. 6, 1985, pages 842 - 844
BERTOLINI ET AL., J. MED. CHEM., vol. 40, 1997, pages 2011 - 2016
BOWSER ET AL., BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 5652 - 5655
CDC EMERG. INFECT. DIS., vol. 5, no. 4, 2004, pages 552 - 555
CHAUDHURI ET AL., J.ORG. CHEM., vol. 72, 2007, pages 1912 - 1923
CHAUDHURI P ET AL: "An Experimental and Computational Analysis on the Differential Role of the Positional Isomers of Symmetric Bis-2-(pyridyl)-1H-benzimidazoles as DNA Binding Agents", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON.; US, vol. 72, no. 6, 16 March 2007 (2007-03-16), pages 1912 - 1923, XP002567486, ISSN: 0022-3263, [retrieved on 20070217], DOI: 10.1021/JO0619433 *
CLIN. INF. DIS., vol. 45, no. S2, 2007, pages S122 - S128
CLIN. INF. DIS., vol. 46, no. S1, 2008, pages S32 - S42
CLIN. INFECT. DIS., vol. 38, 2004, pages 1279 - 1286
CMAJ, vol. 171, no. 1, 2004, pages 33 - 38
CMAJ, vol. 179, no. 8, 2008, pages 767 - 772
ENGLEBIENNE, MED. CHEM., vol. 1, no. 3, 2005, pages 215 - 226
GOODMAN, GOLDMAN'S: "The Pharmacological Basis of Therapeutics", pages: 1707 - 1711
GUILES J ET AL: "New agents for Clostridium difficile-associated disease", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 17, no. 11, 1 January 2008 (2008-01-01), pages 1671 - 1683, XP002567961, ISSN: 1354-3784, DOI: 10.1517/13543780802434279 *
HELICOBACTER., vol. 10, no. 3, 2005, pages 157 - 171
INFECT CONT. HOSP. EPIDEMIOL., vol. 28, 2007, pages 920 - 5
J. ANTIMICROB. CHEM., vol. 51, 2003, pages 1339 - 1350
J. ANTIMICROB. CHEM., vol. 53, 2004, pages 882 - 884
J. INT. MED., vol. 243, no. 3, 1998, pages 251 - 253
J. MED. MICROBIOL., vol. 54, 2005, pages 101 - 111
JAMA, vol. 269, 1993, pages 71 - 5
JAMA, vol. 294, no. 23, 2005, pages 2989 - 2995
KUSHNER ET AL., CAN J PHYSIOL PHARMACOL., vol. 77, no. 2, 1999, pages 79 - 88
LE SANN C ET AL: "New mustard-linked 2-aryl-bis-benzimidazoles with anti-proliferative activity", ORGANIC AND BIOMOLECULAR CHEMISTRY 2006 ROYAL SOCIETY OF CHEMISTRY GB, vol. 4, no. 7, 2006, pages 1305 - 1312, XP002659715, DOI: DOI:10.1039/B600567E *
LEFFLER D A ET AL: "Treatment of Clostridium difficile-Associated Disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 136, no. 6, 1 May 2009 (2009-05-01), pages 1899 - 1912, XP026148020, ISSN: 0016-5085, [retrieved on 20090507], DOI: 10.1053/J.GASTRO.2008.12.070 *
M11-A7, vol. 27, 2 January 2007 (2007-01-02)
M7-A7, vol. 26, 2 January 2006 (2006-01-02)
MED. SCI. MONIT., vol. 7, no. 4, 2001, pages 751 - 754
POSTGRAD. MED. J., vol. 66, no. 777, 1990, pages 582
REMINGTON: "The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS AND WILKINS
TACKE, ZILCH, ENDEAVOUR, 1986, pages 191 - 197

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019371A1 (fr) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Composés organiques volatils (cov) utilisables en vue du diagnostic de la diarrhée associée à clostridium difficile (dacd)
US10444123B2 (en) 2014-08-01 2019-10-15 The Brigham And Women's Hospital, Inc. Volatile organic compounds (VOCs) for the diagnosis of Clostridium difficile-associated diarrhea (CDAD)
EP3628669A1 (fr) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Nouveaux composés en tant qu'inhibiteurs de la nadph oxydase
WO2020065048A1 (fr) * 2018-09-28 2020-04-02 Genkyotex Suisse Sa Nouveaux composés utilisés en tant qu'inhibiteurs de la nadph oxydase
CN112930346A (zh) * 2018-09-28 2021-06-08 金其尤泰克斯瑞士股份有限公司 作为nadph氧化酶抑制剂的新型化合物
JP2022502425A (ja) * 2018-09-28 2022-01-11 ジャンキョテックス スイス エスアーGenkyotex Suisse Sa Ｎａｄｐｈオキシダーゼ阻害剤としての新規化合物
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Similar Documents

Publication Publication Date Title
US9763925B2 (en) Antibacterial compounds
US9278091B2 (en) Compounds for the treatment of Clostridium difficile associated disease
WO2011151618A2 (fr) Composés pour le traitement d'une maladie associée à clostridium difficile
WO2011151619A1 (fr) Composés destinés au traitement d'une maladie associée à clostridium difficile
GB2482502A (en) Novel compounds for use in the treatment of Clostridium Difficile and associated diseases
WO2011151620A1 (fr) Composés pour le traitement d'une maladie associée à clostridium difficile
GB2480813A (en) Compounds for the treatment of clostridium difficile-associated disease
RU2575477C2 (ru) Соединения для лечения заболеваний, связанных с clostridium difficile
GB2480814A (en) Compounds for the treatment of clostridium difficile-associated disease
GB2480815A (en) Compounds for the treatment of clostridium difficile-associated disease
GB2482501A (en) Novel compounds for use in the treatment of Clostridium Difficile and associated diseases
GB2480816A (en) Compounds for the treatment of Clostridium difficile associated diseases
WO2011151617A1 (fr) Composés pour le traitement d'une maladie associée à clostridium difficile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11728025

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11728025

Country of ref document: EP

Kind code of ref document: A1